Journal article icon

Journal article

Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma.

Abstract:

Clinical trials have demonstrated that rituximab improves overall survival in non-Hodgkin lymphoma (NHL), except in mantle cell lymphoma (MCL). We used Surveillance Epidemiology and End Results (SEER)-Medicare data to compare survival in older MCL patients who began chemotherapy with or without rituximab within 180 days of diagnosis. Patients were followed from diagnosis (January 1999 to December 2005) until death or the end of observation (December 2007). Medicare administrative and claims d...

Expand abstract

Actions


Access Document


Authors


Journal:
Blood
Volume:
118
Issue:
18
Pages:
4808-4816
Publication date:
2011-11-01
DOI:
EISSN:
1528-0020
ISSN:
0006-4971
Source identifiers:
359191

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP